Antibiotics for Staphylococcus aureus pneumonia in adults

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Shankar, Pinakini K ^a   Devi, V ^b   Bairy, K L ^b   Nair, S ^b  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; LINCOSAMIDE; MEROPENEM; METICILLIN; NAFCILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; TETRACYCLINE DERIVATIVE; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 44949190579     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006337     Document Type: Review

References (20)

1. ATS 2001 American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. American Journal of Critical Care 2001;163:1730-54.
2. ATS 2005 American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005;171:388-416.
3. Barber 1961 Barber M. Methicillin resistant staphylococci. Journal of Clinical Pathology 1961;14:385-93.
4. Betriu 2001 Betriu C, Redondo M, Boloix A, et al.Comparative activity of linezolid and other new agents againstmethicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. Journal of Antimicrobial Chemotherapy 2001;48:911- 3.
5. BTS 2001 British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001;56(Suppl IV):1-64.
6. CCAPWG 2000 Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clinical Infectious Diseases 2000;31:383-421.
7. CDC 1997 Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-United States 1997. Morbidity and Mortality Weekly Report 1997;46:813-5.
8. De La Cruz 2004 De LaCruz R, Johnson B, Christensen D, et al.Emergence of Staphylococcus aureus as etiology of bacteremic community acquired pneumonia. Results from the Community Acquired Pneumonia Organization (CAPO) International Study. ICCAC Scientific Meeting. 2004.
9. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. 1994 BMJ;309:1286-91.
10. Egger 1997 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
11. El-Solh 2001 El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. American Journal of Respiratory Critical Care Medicine 2001;163:645-51.
12. Hiramatsu 1997 Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 1997;40:135-6.
13. IDSA 2003 Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases 2003;37:1405- 33.
14. Jadad 1996 Jadad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
15. Jarvis 1992 Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. Journal of Antimicrobial Chemotherapy 1992;29:19-24.
16. Low 1997 Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 1997;39:53-8.
17. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. JAMA 1995;273:408-12.
18. Spencer 1996 Spencer RC. Predominant pathogens found in the European Prevalance of Infection in Intensive Care Study. European Journal of Clinical Microbiology and Infectious Diseases 1996;15:281-5.
19. Sterne 2001 Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication bias and other biases. In: EggerM, Davey SmithG, AltmanDG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Books, 2001.
20. Wunderink 2003 Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97.